Endothelin blockers and renal protection: A new strategy to prevent end- organ damage in cardiovascular disease?

Cardiovascular Research

Volumn 39, Issue 3, 1998, Pages 543-549

  Rabelink, Ton J ^a   Stroes, Erik S G ^a   Bouter, K Paul ^b   Morrison, Paul ^c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c U Gene Clinical Pharmacology Unit   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

27 O 3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ATRASENTAN; BOSENTAN; CGS 26582; CGS 31447; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PD 069185; SITAXSENTAN; TAK 044; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; HUMAN; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ASPARTIC ENDOPEPTIDASES; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; ENDOTHELIN-1; ENZYME INHIBITORS; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY FAILURE, CHRONIC; METALLOENDOPEPTIDASES; RECEPTORS, ENDOTHELIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0032168323     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00155-2     Document Type: Review

References (102)

1. Yanagisawa M., Kurihara H., Kimura S.et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 322:1988;411-415.
2. Xu D., Emoto N., Giaid A.et al. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 78:1994;473-485.
3. Emoto N., Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phophoramidon sensitive metalloprotease with acidic pH optimum. J Biol Chem. 270(25):1995;15262-15268.
4. Karet F.E., Davenport A.P. Localization of endothelin peptides in human kidney. Kidney Int. 49:1996;382-387.
5. Pupilli C., Romagnani P., Lasagni L.et al. Localization of endothelin-converting enzyme 1 in human kidney. Am J Physiol. 273:1997;F749-F756.
6. Murer L., Zachello G., Basso G.et al. Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome. Am J Nephrol. 14:1994;157-161.
7. Kohan D.E. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 29(1):1997;2-26.
8. Webb D.J., Monge J.C., Rabelink T.J., Yanagisawa M. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol Sci. 19:1998;5-8.
9. Ong A.C. Perspectives in endothelin research: tubulointerstitial actions of endothelins in the kidney: roles in health and disease. Nephrol Dial Transplant. 11(2):1996;251-257.
10. b receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation. 92:1995;357-363.
11. Kaasjager H.A.H., Shaw S., Koomans H.A., Rabelink T.J. Role of endothelin receptor subtypes in the systemic and renal response to endothelin-1 in humans. J Am Soc Nephrol. 8:1997;32-39.
12. Badr K.F., Murray J.J., Breyer M.D.et al. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest. 83:1989;336-342.
13. Lanese D.M., Yuan B.H., McMurtry I.F., Conger J.D. Comparative sensitivities of isolated rat renal arterioles to endothelin. Am J Physiol. 263:1992;F894-F899.
14. Takahashi K., Katoh T., Fukunaga M., Badr K.F. Studies on the glomerular microcirculatory actions of manidipine and its modulation of the systemic and renal effects of endothelin. Am Heart J. 125:1993;609-619.
15. Rabelink T.J., Kaasjager K.A.H., Boer P.et al. Effects of endothelin-1 on renal function in humans: Implications for physiology and pathophysiology. Kidney Int. 46:1994;376-381.
16. Bijlsma J.A., Rabelink T.J., Kaasjager K.A.H., Koomans H.A. Jr. L-Arginine does not prevent the renal effects of endothelin in humans. J Am Soc Nephrol. 5:1995;1508-1516.
17. Tomita K., Ujie K., Nakanishi T.et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 324:1989;1127-1131.
18. Oken D.E. Theoretical analysis of pathogenetic mechanisms in experimental acute renal failure. Kidney Int. 24:1993;16-26.
19. Fogo A., Hellings S., Inagami T., Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 42:1992;770-774.
20. Gellai M., Jugus M., Fletcher T., Dewolf R., Nambi P. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J Clin Invest. 93:1994;900-906.
21. Bunchmann T.E., Brookshire C.A. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest. 88:1991;310-314.
22. Nakahama H. Stimulatory effect of cyclosporine A on endothelin secretion by a cultured renal epithelial line, LLC-PK1 cells. Eur J Pharmacol. 180:1990;191-192.
23. Heyman S.N., Clark B.A., Kaiser N.et al. Radiocontrast agents induce endothelin release in vivo and in vitro. J Am Soc Nephrol. 3:1992;58-62.
24. Mino N., Kobayashi M., Nakajima A.et al. Protective effects of a selective endothelin receptor antagonist, BQ-123, in ischaemic acute renal failure in rats. Eur J Pharmacol. 221:1992;77-81.
25. Morise Z., Ueda M., Aiura K., Endo M., Kitajima M. Pathophysiologic role of endothelin 1 in renal function in rats with endotoxin shock. Surgery. 115:1994;199-204.
26. Kivlighn S.D., Gabel R.A., Siegl P.K.S. Effects of BQ-123 on renal function and acute cyclosporine induced renal function. Kidney Int. 45:1994;131-136.
27. Abassi Z.A., Pieruzzi F., Nakhoul F., Keiser H.R. Effects of cyclosporin A on the synthesis, excretion and metabolism of endothelin in the rat. Hypertension. 27:1996;1140-1148.
28. Fukuda K., Yanagida T., Okuda S.et al. Role of endothelin as a mitogen in experimental glomerulonephritis in rats. Kidney Int. 49:1996;1320-1329.
29. Battistini B., Chailler P., D'Orleans-Juste P., Briere N., Sirois P. Growth regulatory properties of endothelins. Peptides. 14:1993;385-399.
30. Ruiz-Ortega M., Gomez-Garre D., Alcazar R.et al. Involvement of angiotensin II and endothelin in matrix protein production and renal sclerosis. J Hypertens. 12(suppl 4):1994;S51-S58.
31. Benigni A., Perico N., Gaspari F.et al. Increased renal endothelin production in rats with reduced renal mass. Am J Physiol. 260:1991;F331-F339.
32. Orisio S., Benigni A., Bruzzi I.et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 43:1993;354-358.
33. Bruzzi I., Remuzzi G., Benigni A. Endothelin: a mediator of renal disease progression. J Nephrol. 10(4):1997;179-183.
34. Hocher B., Thone-Relneke C., Rohmeles P.et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis and renal cysts but not hypertension. J Clin Invest. 99:1997;1380-1389.
35. United States Renal Data System, USRDS 1996 Annual Data Report, the National Institute of Health, National Institute of Diabetes and Digestive Kidney Diseases. Incidence and prevalence of ESRD. Am J Kidney Dis 1996;28(3):S34-S37.
36. Lindner A., Charra B., Sherrard D.J., Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 290:1974;690-701.
37. Raine A.E.G. Report on the management of renal failure in Europe XXII, 1991. Nephrol Dial Transplant. 7(suppl. 2):1992;7-35.
38. Kasiske B.L., Guijarro C., Massy Z.A., Wiederkehr M.R., Ma J.Z. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 7:1996;158-165.
39. Schwab S.J., Paul L.C. Survival with end-stage renal failure in the 1990s. Curr Opin Nephrol Hypertens. 5:1996;477-479.
40. Ruilope L.M. The kidney and cardiovascular disease. Nephrol Dial Transplant. 12:1997;243-245.
41. London G.M., Druecke T.B. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int. 51:1997;1678-1695.
42. Takahashi K., Ghatei M.A., Lam H.C., O'Halloran D.J., Bloom S.R. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 33:1990;306-310.
43. Tarquini B., Perfetto F., Tarquini R., Cornelissen G., Halberg F. Endothelin-1 chronome indicates diabetic and vascular disease chronorisk. Peptides. 18(1):1997;119-132.
44. Lee Y.L., Shin S.J., Tsai J.H. Increased urinary endothelin-1 like immunoreactivity in NIDDM patients with albuminuria. Diabetes Care. 17(4):1994;263-266.
45. Sharma K., Ziyadeh F.N., Alzahabi B.et al. Increased renal production of transforming growth factor b1 in patients with type II diabetes. Diabetes. 46:1997;854-859.
46. Shin S.J., Lee Y.L., Tsai J.H. The correlation of plasma and urine endothelin-1 with the severity of nephropathy in Chinese patients with type 2 diabetes. Scand J Clin Lab Invest. 56(6):1996;571-576.
47. Ferri C., Piccoli A., Properzi G.et al. Insulin stimulates endothelin-1 secretion in vitro and modulates its circulating levels in vivo. J Clin Endocrinol Metab. 80:1995;829-835.
48. Desideri G., Ferri C., Bellini C., De Mattia G., Santucci A. Effects of ACE inhibition on spontaneous and insulin stimulated endothelin-1 secretion. Diabetes. 46:1997;81-86.
49. Ferri C., Carlomagno A., Coassin S.et al. Circulating endothelin-1 levels increase during euglycemic hyperinsulinemic clamp in lean NIDDM men. Diabetes Care. 18:1995;226-233.
50. Fukui M., Makamura T., Ebihara I.et al. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med. 122:1993;149-156.
51. Baumgartner-Parzer S., Wagner O., Nowotny P., Vierhapper H., Waldhausl W. Stimulation of endothelin-1 production by thrombin, but lack of interference by high ambient glucose in vitro. Eur J Endocrinol. 130(3):1994;271-275.
52. Baumgartner-Parzer S., Wagner O., Waldhausl W., Roth T., Lorenzi M. Failure of high ambient glucose to affect endothelin-1 synthesis or release by cultured human endothelial cells. Horm Metab Res. 28(11):1996;610-612.
53. Zoja C., Morigi M., Figliuzzi M.et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis. 26:1995;934-941.
54. Remuzzi G., Ruggenenti P., Benigni A. Understanding the nature of renal disease progression. Kidney Int. 51:1997;2-15.
55. Yard BA, Chorianopoulos E, Woude FJ. Albumin stimulation of endothelin production by proximal tubular epithelial cells is mediated by advanced glycation end-products. Kidney Int (abstract), in press.
56. Nakamura T., Ebihara I., Tomino Y., Koide H. Alteration of growth related proto-oncogene expression in diabetic glomeruli by a specific endothelin receptor A antagonist. Nephrol Dial Transplant. 11:1996;1528-1531.
57. Nakamura T., Ebihara I., Fukui M., Tomino Y., Koide H. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes. 44:1995;895-899.
58. Lariviere R., Day R., Schiffrin E.L. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate salt hypertensive rats. Hypertension. 21:1993;916-920.
59. Lariviere R., Thibault G., Schiffrin E.L. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate salt hypertensive, but not in spontaneously hypertensive rats. Hypertension. 21:1993;294-300.
60. Schiffrin E.L., Lariviere R., Li J.S., Sventek P. Enhanced expression of endothelin 1 gene in DOCA salt hypertensive rats: correlation with vascular structure. J Vasc Res. 33:1996;235-248.
61. B endothelin receptor antagonist bosentan. Can J Physiol Pharmacol. 73:1995;390-398.
62. Chillon J.M., Heistad D.D., Baumbach G.L. Effects of endothelin receptor inhibition on cerebral arterioles in hypertensive rats. Hypertension. 27:1996;794-798.
63. Sventek P., Turgeon A., Garcia R., Schiffrin E.L. Vascular and cardiac overexpression of endothelin 1 gene in 1-kidney, one clip Goldblatt hypertensive rats but only in the late phase of 2-kidney, 1-clip Goldblatt hypertension. J Hypertens. 14:1996;57-64.
64. Schiffrin E.L., Deng L.Y., Sventek P., Day R. Enhanced expression of endothelin 1 gene in endothelium of resistance arteries in severe human essential hypertension. J Hypertens. 15:1997;57-63.
65. Haynes W.G., Ferro C.J., O'Kane K.P.J.et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 93:1996;1860-1870.
66. Kiowski W., Sutsch G., Hunziker P.et al. Evidence for ET-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
67. Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V. The effect of an endothelin receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 338:1998;784-790.
68. Ergul S., Parish D.C., Puett D., Ergul A. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 28(4):1996;652-655.
69. Verhagen A.M.G., Rabelink T.J., Braam B.et al. Endothelin-A receptor blockade alleviates hypertension and renal lesions with chronic nitric oxide blockade. J Am Soc Nephrol. 9(5):1998;755-762.
70. Barton M., Vos I., Shaw S.et al. Local renal endothelin mediates glomerular injury and vascular dysfunction in Dahl salt-sensitive hypertension. Hospitalis. 68(1/2):1998;11s.
71. th International Conference on Endothelin. Kyoto, Japan 1997.
72. Kohno M., Yokokawa K., Yasunari K.et al. Renoprotective effects of a combined endothelin type A/ type B receptor antagonist in experimental malignant hypertension. Metabolism. 46(9):1997;1032-1038.
73. Opgenorth T., Wu Wong J.R., Shiosaki K. Endothelin converting enzymes. FASEB J. 6:1992;2653-2659.
74. De Lombaert S., Ghai R.D., Jeng A.Y., Trapani A.J., Webb R.L. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin converting enzyme. Biochem Biophys Res Commun. 204(1):1994;407-412.
75. Tsurumi Y., Ohhata N., Iwamoto T.et al. WS 79089A, B and C; new endothelin converting enzyme inhibitors isolated from streptosporangium roseum No. 79089. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. J Antibiot Tokyo. 47(6):1994;619-630.
76. Disashi T., Nonoguchi H., Iwaoka T.et al. Endothelin converting enzyme-1 gene expression in the kidney of spontaneously hypertensive rats. Hypertension. 30:1997;1591-1597.
77. Morawietz H., Szibor M., Ruckschloss U.et al. Upregulation of endothelin converting enzyme 1 mRNA in atrial myocardium of patients with end-stage heart failure. Hospitalis. 67(1/2):1998;24S.
78. Lipkin G.W., Dawnay A.B., Cattell W.R., Raine A.E. Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate renal failure. Kidney Int. 52:1997;792-801.
79. Haynes W.G., Webb D.J. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 344:1994;852-854.
80. Ferro J.C., Spratt J.C., Haynes W.G., Webb D.J. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Hospitalis. 68(1/2):1998;14S.
81. Tikkanen I., Johnston C.I. Comparison of renin angiotensin to calcium channel blockade in renal disease. Kidney Int. 52(suppl 63):1997;S19-S23.
82. Nielsen F.S., Rossing P., Bang L.E.et al. On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes. 44:1995;783-789.
83. Jensen T., Bjerre-Knudsen J., Feldt-Rasmussen B., Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet. 1:1989;461-464.
84. Ruggenenti P., Perna A., Mosconi L.et al. Proteinuria predicts end-stage renal failure in non diabetic chronic nephropathies. Kidney Int. 52(suppl.63):1997;S54-S57.
85. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 32:1989;219-226.
86. Jerums G., Panagiotopoulos S., Tsalamandris C. Why is proteinuria such an important risk factor for progression in clinical trials? Kidney Int. 52(suppl 63):1997;S87-S92.
87. Gansevoort R.T., Navis G.J., Wapstra F.H., Jong P.E. de Proteinuria and progression of renal disease. Therapeutic implications. Curr Opin Nephrol Hypertens. 6:1997;133-140.
88. Benigni A., Colosio V., Brena C.et al. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes. 47:1998;450-456.
89. Viberti G., Chatuverdi N. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria. Kidney Int. 52(suppl 63):1997;S32-S35.
90. GISEN group. Randomised placebo controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non diabetic nephropathy. Lancet 1997;349:1857-1863.
91. Chua B.H.L., Chua C.C., Diglio C.A., Siu B.B. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta. 1178:1993;201-206.
92. Kohno M., Horio T., Ikeda M.et al. Angiotensin II stimulates endothelin 1 secretion in cultured rat mesangial cells. Kidney Int. 42:1992;860-866.
93. Bakris G.L., Re R.N. Endothelin modulates angiotensin II induced mitogenesis of human mesangial cells. Am J Physiol. 264:1993;F937-F942.
94. Dohi Y., Hahn A.W., Boulanger C.M., Buhler F.R., Luscher T.F. Endothelin stimulated by angiotensin II augments contractility of spontaneous hypertensive rat resistance arteries. Hypertension. 19:1992;131-137.
95. Barton M., Shaw S., d'Uscio L.V., Moreau P., Luscher T.F. Angiotensin II increases vascular and renal endothelin 1 and functional endothelin converting enzyme activity in vivo: Role of Eta receptors for endothelin regulation. Biochem Biophys Res Commun. 238:1997;861-865.
96. Moreau P., d'Uscio L.V., Shaw S.et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy. Reversal by Eta-receptor antagonist. Circulation. 96:1997;1593-1597.
97. Rajagopalan S., Laursen J.B., Borthayre A.et al. Role for endothelin 1 in angiotensin II mediated hypertension. Hypertension. 30:1997;29-34.
98. Ruiz-Ortega M., Gomez-Garre D., Liu X.H.et al. Quinapril decreases renal endothelin 1 expression and synthesis in a normotensive model of immune complex nephritis. J Am Soc Nephrol. 8:1997;756-758.
99. Li J.S., Knafo L., Turgeon A., Garcia R., Schiffrin E.L. Effect of endothelin antagonist on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol. 40:1996;H88-H93.
100. Kaasjager HA, Koomans HA, Rabelink TJ. Endothelin-1 induced vasopressor responses in essential hypertension. Hypertension 1997;30:15-21.
101. Verhaar M.C., Strachan F.E., Newby D.E.et al. Blockade of endothelin A (ETA) receptor increases endogenous NO generation. Circulation. 97(8):1998;752-756.
102. Potter G.S., Johson R.J., Fink G.D. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension. 30:1997;1578-1584.